ScandiDos has completed a directed share issue to IBA Dosimetry of 4,150,000 shares at a subscription price of 3 SEK per share, whereby the company receives approximately 12,45 million SEK before transaction costs.
The strategic alliance that is being created between ScandiDos and IBA in quality assurance for radiation therapy enables a collaboration between the parties in product development, marketing, and distribution in selected markets, the company states in a press release.
“By partnering with IBA, a leading industry player, ScandiDos will be able to reach more customers globally and help make radiation treatments even safer than they are today. This strategic collaboration will allow us to maintain our independence to continue to develop our business while benefiting from IBA’s strong operational capabilities,” said Gustaf Piehl, CEO ScandiDos, in the press release.
ScandiDos intends to use the proceeds from the issue to finance the continued implementation of the company’s strategic and operational plans, it states.